- Home
- SER vs ACET Comparison
SER vs ACET Comparison
Compare SER & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- ACET
- Stock Information
- Founded
- SER 2017
- ACET 1947
- Country
- SER United States
- ACET United States
- Employees
- SER N/A
- ACET N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- ACET Health Care
- Exchange
- SER Nasdaq
- ACET Nasdaq
- Market Cap
- SER 53.5M
- ACET 44.4M
- IPO Year
- SER 2018
- ACET N/A
- Fundamental
- Price
- SER $5.80
- ACET $0.60
- Analyst Decision
- SER Strong Buy
- ACET Buy
- Analyst Count
- SER 1
- ACET 6
- Target Price
- SER $11.00
- ACET $6.00
- AVG Volume (30 Days)
- SER 12.2K
- ACET 477.8K
- Earning Date
- SER 05-24-2025
- ACET 05-16-2025
- Dividend Yield
- SER N/A
- ACET N/A
- EPS Growth
- SER N/A
- ACET N/A
- EPS
- SER N/A
- ACET N/A
- Revenue
- SER $56,000.00
- ACET N/A
- Revenue This Year
- SER N/A
- ACET N/A
- Revenue Next Year
- SER N/A
- ACET N/A
- P/E Ratio
- SER N/A
- ACET N/A
- Revenue Growth
- SER N/A
- ACET N/A
- 52 Week Low
- SER $3.81
- ACET $0.45
- 52 Week High
- SER $14.57
- ACET $1.87
- Technical
- Relative Strength Index (RSI)
- SER 55.22
- ACET 44.78
- Support Level
- SER $5.12
- ACET $0.61
- Resistance Level
- SER $6.61
- ACET $0.70
- Average True Range (ATR)
- SER 0.49
- ACET 0.05
- MACD
- SER -0.01
- ACET 0.02
- Stochastic Oscillator
- SER 56.45
- ACET 49.89
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.